Discordance of microsatellite instability and mismatch repair immunochemistry occurs depending on the cancer type.


Journal

Human pathology
ISSN: 1532-8392
Titre abrégé: Hum Pathol
Pays: United States
ID NLM: 9421547

Informations de publication

Date de publication:
05 2023
Historique:
received: 06 08 2022
revised: 12 11 2022
accepted: 27 12 2022
medline: 18 4 2023
pubmed: 4 1 2023
entrez: 3 1 2023
Statut: ppublish

Résumé

Microsatellite instability (MSI) and deficiency of mismatch repair (dMMR) are key markers for predicting the response of immune checkpoint inhibitors (ICIs) and screening for Lynch syndrome (LS). This study examined the incidences of and factors associated with the concordance of MSI and MMR in human cancers. A total of 518 formalin-fixed cancer tissues were analyzed for MSI and MMR immunohistochemistry (IHC). MSI was analyzed by a PCR-based method using Promega markers. Concordance with MMR expression and factors associated with concordance were analyzed. In 2 colorectal cancer samples, MMR IHC failed due to inadequate staining conditions. In the remaining 516 cancers, a high level of MSI (MSI-H) was identified in 113 cases, and dMMR was identified in 112. The concordance of MSI and MMR IHC was 98.3%. Only 9 cases (4 pancreatobiliary, 3 colorectal, and 2 endometrial cancers) were discordant. Of the 113 MSI-H cases, 4 (3.5%) were proficient MMR (pMMR); of the 403 microsatellite stability (MSS) cases, 5 (1.2%) were dMMR. The independent factors associated with MSI-H/dMMR included meeting Amsterdam II criteria, assay purpose, and sampling method. Multivariate analysis revealed that cancer type (gastrointestinal cancers or others) was associated with concordance of MSI and MMR IHC. Three LS cases with pancreatic or endometrial cancer demonstrated MSS and dMMR, and one biliary cancer showed MSI-H and pMMR. Discordance between MSI and MMR IHC occasionally occurs in pancreaticobiliary and endometrial cancers. When suspected, both MSI and MMR IHC should be done to judge the ICI indication and screen for LS.

Identifiants

pubmed: 36596344
pii: S0046-8177(22)00293-3
doi: 10.1016/j.humpath.2022.12.016
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

54-64

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Auteurs

Hiroyuki Matsubayashi (H)

Division of Genetic Medicine Promotion, Shizuoka, 411-8777, Japan; Division of Endoscopy, Shizuoka, 411-8777, Japan. Electronic address: h.matsubayashi@scchr.jp.

Takuma Oishi (T)

Division of Pathology, Shizuoka, 411-8777, Japan.

Keiko Sasaki (K)

Division of Pathology, Shizuoka, 411-8777, Japan.

Masato Abe (M)

Division of Pathology, Shizuoka, 411-8777, Japan.

Yoshimi Kiyozumi (Y)

Division of Genetic Medicine Promotion, Shizuoka, 411-8777, Japan.

Satomi Higashigawa (S)

Division of Genetic Medicine Promotion, Shizuoka, 411-8777, Japan.

Fumitaka Niiya (F)

Division of Endoscopy, Shizuoka, 411-8777, Japan.

Junya Sato (J)

Division of Endoscopy, Shizuoka, 411-8777, Japan.

Hirotoshi Ishiwatari (H)

Division of Endoscopy, Shizuoka, 411-8777, Japan.

Kenichiro Imai (K)

Division of Endoscopy, Shizuoka, 411-8777, Japan.

Kinichi Hotta (K)

Division of Endoscopy, Shizuoka, 411-8777, Japan.

Yoshihiro Kishida (Y)

Division of Endoscopy, Shizuoka, 411-8777, Japan.

Kazunori Takada (K)

Division of Endoscopy, Shizuoka, 411-8777, Japan.

Hiroyuki Ono (H)

Division of Endoscopy, Shizuoka, 411-8777, Japan.

Kenichiro Yamazaki (K)

Division of Gastrointestinal Oncology, Shizuoka, 411-8777, Japan.

Hirofumi Yasui (H)

Division of Genetic Medicine Promotion, Shizuoka, 411-8777, Japan; Division of Gastrointestinal Oncology, Shizuoka, 411-8777, Japan.

Hirotsugu Kenmotsu (H)

Division of Genetic Medicine Promotion, Shizuoka, 411-8777, Japan; Division of Thoracic Oncology, Shizuoka, 411-8777, Japan.

Nobuhiro Kado (N)

Division of Genetic Medicine Promotion, Shizuoka, 411-8777, Japan; Division of Gynecology, Shizuoka, 411-8777, Japan.

Hiroyasu Kagawa (H)

Division of Colon and Rectal Surgery, Shizuoka, 411-8777, Japan.

Akio Shiomi (A)

Division of Colon and Rectal Surgery, Shizuoka, 411-8777, Japan.

Teichi Sugiura (T)

Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka, 411-8777, Japan.

Etsuro Bando (E)

Division of Gastric Surgery, Shizuoka, 411-8777, Japan.

Seiichiro Nishimura (S)

Division of Genetic Medicine Promotion, Shizuoka, 411-8777, Japan; Division of Breast Surgery, Shizuoka, 411-8777, Japan.

Keiichi Hatakeyama (K)

Division of Clinical Research Center, Shizuoka Cancer Center, Shizuoka, 411-8777, Japan.

Masakuni Serizawa (M)

Division of Clinical Research Center, Shizuoka Cancer Center, Shizuoka, 411-8777, Japan.

Rina Harada (R)

Division of Genetic Medicine Promotion, Shizuoka, 411-8777, Japan.

Takashi Sugino (T)

Division of Pathology, Shizuoka, 411-8777, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH